Profile data is unavailable for this security.
About the company
CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
- Revenue in HKD (TTM)230.11m
- Net income in HKD-428.53m
- Incorporated2015
- Employees93.00
- LocationCStone Pharmaceuticals1000 Zhangheng Road Bldg 25Pudong New DistrictSUZHOU 200072ChinaCHN
- Phone+86 51 287186550
- Websitehttps://www.cstonepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tong Ren Tang Technologies Co Ltd | 7.90bn | 490.60m | 5.42bn | 3.89k | 11.04 | 0.6534 | 4.36 | 0.6862 | 0.383 | 0.383 | 6.16 | 6.47 | 0.482 | 0.8615 | 6.00 | 1,978,414.00 | 5.47 | 7.44 | 8.57 | 12.07 | 39.82 | 42.21 | 11.34 | 15.10 | 2.79 | -- | 0.1913 | 39.34 | 7.18 | 10.15 | -11.59 | 4.55 | -8.30 | 3.37 |
| Ocumension Therapeutics | 617.89m | -283.25m | 5.42bn | 505.00 | -- | 1.30 | -- | 8.78 | -0.3781 | -0.3781 | 0.8251 | 5.10 | 0.1571 | 4.30 | 3.35 | 1,263,572.00 | -7.20 | -24.03 | -7.62 | -25.71 | 42.58 | 58.38 | -45.84 | -400.90 | 4.86 | -- | 0.0223 | -- | 69.38 | 365.95 | 29.36 | -- | 213.01 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.71bn | 515.36m | 7.13bn | 789.00 | 13.84 | 1.77 | 11.36 | 4.17 | 0.6157 | 0.6157 | 2.04 | 4.81 | 0.3878 | 0.4134 | 4.92 | 2,185,246.00 | 12.14 | 15.34 | 13.34 | 17.17 | 63.00 | 68.94 | 31.29 | 39.16 | 11.43 | -- | 0.0327 | 52.52 | 5.69 | 2.38 | -7.42 | -2.09 | 20.50 | 8.76 |
| SSY Group Ltd | 4.58bn | 658.92m | 7.13bn | 5.70k | 11.03 | 0.9985 | 6.35 | 1.56 | 0.223 | 0.223 | 1.55 | 2.46 | 0.3616 | 2.27 | 2.11 | 751,065.60 | 5.27 | 9.41 | 6.34 | 12.43 | 42.68 | 56.47 | 14.58 | 17.65 | 2.40 | 14.91 | 0.346 | 42.91 | -10.67 | 4.49 | -19.53 | -1.36 | -8.36 | 9.73 |
| China Shineway Pharmaceutical Group Ltd | 3.80bn | 941.22m | 7.56bn | 2.87k | 7.34 | 0.8517 | 9.66 | 1.99 | 1.25 | 1.25 | 5.03 | 10.73 | 0.3299 | 1.15 | 3.81 | 1,180,191.00 | 8.17 | 8.29 | 10.75 | 10.38 | 73.36 | 74.83 | 24.77 | 18.67 | 3.39 | -- | 0.0419 | 37.49 | -16.35 | 6.90 | -13.35 | 10.80 | 8.92 | 19.39 |
| CStone Pharmaceuticals | 230.11m | -428.53m | 9.24bn | 93.00 | -- | 23.86 | -- | 40.15 | -0.3288 | -0.3288 | 0.1776 | 0.2624 | 0.1487 | 1.38 | 1.68 | 1,704,542.00 | -27.69 | -39.13 | -54.45 | -60.19 | -12.18 | 66.69 | -186.23 | -170.86 | 1.20 | -29.83 | 0.554 | -- | -12.21 | -- | 75.16 | -- | -- | -- |
| Luye Pharma Group Ltd | 7.01bn | 451.08m | 9.67bn | 5.12k | 20.18 | 0.5452 | 6.01 | 1.38 | 0.1199 | 0.1199 | 1.86 | 4.44 | 0.2083 | 2.42 | 2.37 | 1,361,039.00 | 1.91 | 1.98 | 3.26 | 3.16 | 66.85 | 68.37 | 9.15 | 8.04 | 1.24 | 2.35 | 0.4227 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| China Traditional Chinese Med Hldg CoLtd | 17.71bn | -300.96m | 9.77bn | 15.58k | -- | 0.4152 | 10.70 | 0.5515 | -0.0598 | -0.0598 | 3.52 | 4.67 | 0.4326 | 1.59 | 1.71 | 1,057,360.00 | -0.93 | 3.48 | -1.42 | 5.24 | 47.66 | 54.69 | -2.15 | 7.39 | 1.51 | 9.55 | 0.1333 | 21.27 | -8.90 | 2.89 | -95.79 | -49.14 | -15.28 | -48.82 |
| Hbm Holdings Ltd | 904.99m | 571.49m | 9.91bn | 210.00 | 15.38 | 4.09 | 16.57 | 10.95 | 0.741 | 0.741 | 1.15 | 2.79 | 0.3856 | 6.32 | 32.64 | 5,801,203.00 | 24.77 | -42.87 | 30.77 | -53.24 | 92.95 | 96.12 | 64.25 | -292.58 | 6.02 | 28.63 | 0.1857 | -- | -57.43 | 47.71 | -87.81 | -- | -55.31 | -- |
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -100.00bn | -100.00bn | 11.24bn | 105.00 | -- | 13.17 | -- | -- | -- | -- | -- | 1.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Fujian Haixi Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 11.41bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 47.39 | -- | 15.86 | -- | -- | -- |
| Everest Medicines Ltd | 967.41m | -748.61m | 11.98bn | 722.00 | -- | 2.49 | -- | 12.38 | -2.32 | -2.32 | 2.99 | 13.62 | 0.1684 | 13.97 | 3.04 | 1,454,751.00 | -13.03 | -29.28 | -14.21 | -31.67 | 69.92 | -- | -77.38 | -1,040.86 | 5.43 | -- | 0.1577 | -- | 461.16 | -- | -23.32 | -- | 16.96 | -- |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.38bn | -91.63m | 12.80bn | 2.77k | -- | 2.58 | -- | 5.37 | -0.0098 | -0.0098 | 0.2583 | 0.542 | 0.1894 | 1.49 | 3.86 | 893,796.30 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
Data as of Mar 05 2026. Currency figures normalised to CStone Pharmaceuticals's reporting currency: Hong Kong Dollar HKD
11.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GIC Pte Ltd. (Investment Management)as of 23 Dec 2025 | 118.89m | 8.06% |
| HBM Partners AG (Investment Management)as of 31 Dec 2025 | 19.81m | 1.34% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 14.24m | 0.97% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2025 | 5.39m | 0.37% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 4.11m | 0.28% |
| Principal Asset Management Co. (Asia) Ltd.as of 31 Dec 2025 | 3.45m | 0.23% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 3.31m | 0.22% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 2.46m | 0.17% |
| HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Dec 2025 | 1.94m | 0.13% |
| Templeton Asset Management Ltd.as of 31 Jan 2026 | 1.92m | 0.13% |
More ▼
Data from 30 Jun 2025 - 24 Feb 2026Source: FactSet Research Systems Inc.
